Elite Launch Architecture for Advanced Metabolic Therapies
We help biotechs de-risk U.S. launches for GLP-1, dual and triple agonists, and modern obesity therapies by aligning evidence, access, and field execution.
The boutique your board hires when the launch cannot fail
Upper Echelon Management is a principal-led launch and retention architecture firm for advanced metabolic and obesity innovators. We combine 70% commercial rigor with 30% clinical fluency -- the exact blend that makes CCOs, payers, and physicians trust that your asset is clinically inevitable, not optional.
Unlike global strategy houses that hand off to junior teams, or contract organizations that sell volume, we stay in the room from day one through month twelve. Every engagement is led by our Principal, who has sold and led teams on foundational diabetes and obesity brands at BMS, Novo Nordisk, and Vivus.
EU & Japanese Mid-Cap Biotechs
Bringing their first advanced metabolic or obesity asset to the U.S. market with thin or zero commercial footprint.
U.S. Biotechs with Stalling Launches
In-market or near-launch GLP-1, dual/triple agonists, or obesity drugs facing early discontinuation and payer friction.
Specialty Biopharma Innovators
Companies in oncology support, rare disease, CNS, and other complex categories needing principal-level launch strategy.
Three pillars of launch certainty
Deep expertise where persistence determines value
Cardio-Metabolic
GLP-1, duals, triples, and related CV/renal launches
Obesity & Weight
Next-gen obesity agents and legacy weight-loss therapies
US Market Entry
EU/Japanese biotechs entering the U.S. market
Specialty Biopharma
Oncology support, rare disease, CNS, and complex launches
Selected engagement outcomes
National Field Team Expansion
Mid-cap biotech needed to scale from 25 to 60+ reps for a complex metabolic launch, with full clinical readiness from day one.
Designed squad architecture, ran clinical stress tests on every hire, and achieved top-quartile launch performance in priority territories.
GLP-1 Persistence Program
Early discontinuation rates eroding lifetime value. Standard patient support programs failing to address titration and side-effect drop-off.
Built a Retention Engine integrating nurse liaison, HCP coaching, and loyalty constructs that reduced early discontinuation in pilot populations.
Foreign Biotech US Gateway
EU-based mid-cap with zero US commercial footprint needed a complete launch infrastructure for their first metabolic asset.
Served as de facto Head of US Launch -- built the commercial architecture, hired the initial field team, and aligned KOL and payer narratives.
Obesity Launch Hiring
Generalist recruiters produced three rounds of weak candidates. Launch timeline threatened.
Used clinical stress testing and network-level vetting to deliver a curated slate in 4 weeks. Zero first-year turnover among UEM-vetted hires.
From diagnostic to launch certainty
Stress Test
30-minute diagnostic conversation to identify where your launch is most exposed.
Retention Audit
Quantify leakage, map the patient journey, and deliver a prioritized Retention Blueprint.
Architecture Build
Design launch, retention, and talent architecture. Stand up field model and KOL strategy.
Govern & Optimize
Ongoing governance, war-room facilitation, and real-time optimization of launch KPIs.
Schedule your 30-minute Launch Stress Test
A focused diagnostic conversation with our Principal to identify where your advanced metabolic or obesity launch is most exposed -- and what to do about it.